Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
NCT07733024
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
68Ga-PFD3
Sponsor
Tingting Yuan